HUTCHMED Initiates Phase III Trial for HMPL-760 in Relapsed/Refractory DLBCL in China

HUTCHMED has initiated a Phase III trial of HMPL-760 in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma in China. The trial will enroll approximately 240 patients and evaluate efficacy, safety, and pharmacokinetics. HMPL-760 is a highly potent, selective, and reversible inhibitor of BTK, including wild-type and C481S-mutated BTK. A previous Phase II study showed encouraging results with a manageable safety profile and no unexpected safety signals.